Janus Henderson’s Andy Acker suggests the opportunity for healthcare outperformance is becoming more promising after last year’s difficulties.
![](https://s34456.pcdn.co/wp-content/uploads/2024/03/GettyImages-1300036753-640x360.jpg.optimal.jpg)
Janus Henderson’s Andy Acker suggests the opportunity for healthcare outperformance is becoming more promising after last year’s difficulties.
The Novo Nordisk share price is up 51% over the past year, while Eli Lilly is up 84%.
Part of the Mark Allen Group.